Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sagar Lonial

Showing results (411-420 of 440) with videos related to

Pageof 44
Sort By:
Leukemia|July 4, 2018
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysisBrian A Walker, Konstantinos Mavrommatis, Christopher P Wardell, et al.
The Lancet. Haematology|February 3, 2022
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working GroupNoopur S Raje, Elias Anaissie, Shaji K Kumar, et al.
Nature Cell Biology|October 20, 2015
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signallingRuiting Lin, Shannon Elf, Changliang Shan, et al.
Leukemia|February 26, 2020
Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trialsMaria Gavriatopoulou, Ajai Chari, Christine Chen, et al.
The Lancet. Oncology|August 12, 2016
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myelomaShaji Kumar, Bruno Paiva, Kenneth C Anderson, et al.
Blood|June 10, 2018
Identification of novel mutational drivers reveals oncogene dependencies in multiple myelomaBrian A Walker, Konstantinos Mavrommatis, Christopher P Wardell, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 22, 2014
Older patients with myeloma derive similar benefit from autologous transplantationManish Sharma, Mei-Jie Zhang, Xiaobo Zhong, et al.
Blood Cancer Discovery|September 28, 2023
Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple MyelomaSeth J Welsh, Benjamin G Barwick, Erin W Meermeier, et al.
Blood Cancer Discovery|December 9, 2025
Longitudinal profiling of tumor and immune compartments uncovers patterns of dysregulation and associations with response in multiple myelomaDenis J Ohlstrom, William C Pilcher, Marina E Michaud, et al.
The Lancet. Oncology|September 23, 2014
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trialJesús F San-Miguel, Vânia T M Hungria, Sung-Soo Yoon, et al.
Pageof 44

Showing results (411-420 of 440) with videos related to

Sort By:
Pageof 44
Leukemia|July 4, 2018
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysisBrian A Walker, Konstantinos Mavrommatis, Christopher P Wardell, et al.
The Lancet. Haematology|February 3, 2022
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working GroupNoopur S Raje, Elias Anaissie, Shaji K Kumar, et al.
Nature Cell Biology|October 20, 2015
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signallingRuiting Lin, Shannon Elf, Changliang Shan, et al.
Leukemia|February 26, 2020
Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trialsMaria Gavriatopoulou, Ajai Chari, Christine Chen, et al.
The Lancet. Oncology|August 12, 2016
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myelomaShaji Kumar, Bruno Paiva, Kenneth C Anderson, et al.
Blood|June 10, 2018
Identification of novel mutational drivers reveals oncogene dependencies in multiple myelomaBrian A Walker, Konstantinos Mavrommatis, Christopher P Wardell, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 22, 2014
Older patients with myeloma derive similar benefit from autologous transplantationManish Sharma, Mei-Jie Zhang, Xiaobo Zhong, et al.
Blood Cancer Discovery|September 28, 2023
Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple MyelomaSeth J Welsh, Benjamin G Barwick, Erin W Meermeier, et al.
Blood Cancer Discovery|December 9, 2025
Longitudinal profiling of tumor and immune compartments uncovers patterns of dysregulation and associations with response in multiple myelomaDenis J Ohlstrom, William C Pilcher, Marina E Michaud, et al.
The Lancet. Oncology|September 23, 2014
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trialJesús F San-Miguel, Vânia T M Hungria, Sung-Soo Yoon, et al.
Pageof 44